Endonovo Therapeutics
OTC: ENDVWoodland Hills, US · Founded 2011 · Delaware corporation
Endonovo Therapeutics is a commercial-stage developer of non-invasive, wearable medical devices that deliver its Electroceutical Therapy, which uses bioelectricity to treat inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Its therapy is FDA-cleared and CE-marked for pain, post-surgical edema, and wound healing, with a clinical-stage pipeline targeting ischemic heart disease, concussions, traumatic brain injury, and multiple sclerosis.
Founders & leadership
MM
Michael MannExecutive
AC
Alan CollierExecutive
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 7 rounds · 2013–2019
▶$225KraisedNov 2019 · 4 investors · BiotechnologyRule 506(c)
▶$225KraisedNov 2019 · 4 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Collier CollierExecutive Officer, Director
- Michael MannExecutive Officer
- Offering amount
- $2M
- Amount sold
- $225K
- Minimum investment
- $25K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$700KraisedDec 2017 · 13 investors · BiotechnologyRule 506(c)
▶$700KraisedDec 2017 · 13 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $700K
- Minimum investment
- $25K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$211.3KraisedFeb 2016 · 6 investors · OtherRule 506(c)
▶$211.3KraisedFeb 2016 · 6 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $211.3K
- Minimum investment
- $5K
- Proceeds to insiders
- $50K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
▶$105KraisedDec 2014 · 3 investors · OtherRule 506(c)
▶$105KraisedDec 2014 · 3 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $105K
- Minimum investment
- $5K
- Proceeds to insiders
- $20K
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
▶$12.5KraisedDec 2014 · 1 investors · Other
▶$12.5KraisedDec 2014 · 1 investors · Other
Officers, directors & promoters on the filing
- Alan CollierExecutive Officer, Director
- Michael MannExecutive Officer
- Offering amount
- $25K
- Amount sold
- $12.5K
- Minimum investment
- $5K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 05
▶$50KraisedDec 2014 · 2 investors · OtherRule 506(c)
▶$50KraisedDec 2014 · 2 investors · Other
Rule 506(c)Officers, directors & promoters on the filing
- Michael MannExecutive Officer
- Alan CollierExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $50K
- Minimum investment
- $5K
- Proceeds to insiders
- $20K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
▶$483KraisedAug 2014 · 19 investors · BiotechnologyRule 506(c)
▶$483KraisedAug 2014 · 19 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Alan CollierExecutive Officer, Director
- Michael MannExecutive Officer
- Offering amount
- $500K
- Amount sold
- $483K
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Endonovo Therapeutics do?
- Endonovo Therapeutics is a commercial-stage developer of non-invasive, wearable medical devices that deliver its Electroceutical Therapy, which uses bioelectricity to treat inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Its therapy is FDA-cleared and CE-marked for pain, post-surgical edema, and wound healing, with a clinical-stage pipeline targeting ischemic heart disease, concussions, traumatic brain injury, and multiple sclerosis.
- How much funding has Endonovo Therapeutics raised?
- Endonovo Therapeutics has disclosed $1.8M raised across 7 rounds.
- Where is Endonovo Therapeutics headquartered?
- Endonovo Therapeutics is headquartered in Woodland Hills, US.